Tuesday, May 17, 2011

Genentech, Merck join forces to sell hepatitis C drug regimen

Genentech Inc. and Merck & Co. will combine forces to sell and promote a new three-drug, hepatitis C-fighting regimen in the United States and possibly abroad.
The companies did not disclose the value of the deal, but it centers on Merck’s (NYSE: MRK) recently approved chronic hepatitis C treatment, Victrelis, or boceprevir.

No comments:

Post a Comment